Completed

SAD30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

goLITE

+ Control

Device
Who is being recruted

Mental Disorders+1

+ Depressive Disorder

+ Seasonal Affective Disorder

From 21 to 64 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: January 2012
See protocol details

Summary

Principal SponsorPhilips Respironics
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 6, 2012

Actual date on which the first participant was enrolled.

Participants will be randomly assigned to receive either a 467nm light or a 580nm light. Participants will use the light every day for six weeks for 30 minutes. Multiple assessments and questionnaires will be given weekly to assess the efficacy of the treatment.

Official Title30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder
NCT01462305
Principal SponsorPhilips Respironics
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

35 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 21 to 64 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Mental DisordersDepressive DisorderSeasonal Affective DisorderMood Disorders

Criteria

Inclusion Criteria: 1. Males and females, ages 21-64 2. Able and willing to provide written informed consent 3. History of recurrent major depressive episodes with winter-type seasonal pattern by Diagnostic and Statistical Manual of the American Psychiatric Associated, 4th Ed. (DSM-IV) criteria (American Psychiatric Association, 1990), based on diagnostic interview utilizing the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (First et al., 2007) \*Bipolar I excluded for this study 4. SIGH-ADS score of ≥20 5. Use of the light device as instructed by the study clinician for at least 6 out of 7 days for the first two weeks of therapy and at least 5 out of 7 days for the remaining four weeks of therapy. Exclusion Criteria: 1. Participation in a study of investigational or marketed drugs or devices during the 30-day period prior to the start of the study or during the study 2. Subjects who are medically complicated, medically unstable and/or have other severe diseases, as determined by the investigator. 3. Abnormal TSH level, (outside range of 0.3 to 5.0 mlU/L), as determined by the TSH levels blood test 4. History of concurrent psychiatric illness that would preclude compliance with the protocol and/or ability to complete the study safely 5. History or current diagnosis of Bipolar I Disorder 6. Variable psychiatric symptoms such as rapid cycling or severe premenstrual syndrome that could interfere with accurate assessment of the treatment effect 7. History of a medical condition that affects mood or produces hallmark symptoms of a mood disorder (i.e. hypothyroidism) 8. History of current or recent (within previous 12 months) alcohol, narcotic or other drug abuse by DSM-IV criteria 9. Positive urine drug screen at the Physical Screening 10. Active suicidal or homicidal ideation or plan, as determined by the investigator 11. Global Assessment of Functioning (GAF) \<51 (see Appendix B) 12. Use of light therapy treatment within the previous 6 months or any history of goLITE use 13. Pregnant or lactating (will confirm absence of pregnancy with a urine or serum pregnancy test in females of childbearing potential during the Physical Screening. Additional pregnancy tests may be performed as per individual site requirements). Females of child-bearing potential must agree to use some form of birth control throughout the course 14. Current use or use within 2 months of antidepressants or mood stabilizing medications, even if taken for a non-psychiatric indication 15. Currently working night shift or rotating shift or other habitual alteration of the sleep/wake cycle 16. Planned travel outside of the state in which the trial is being conducted 17. Current use or use within the previous 1 month of photosensitizing medications (amiodarone, benoxaprofen, chlorpromazine, demeclocycline, fleroxacin, nalidixic acid, ofloxacin, piroxicam, porfimer, psoralens, quinidine, temoporfin) or remedies (St. John's wort, melatonin) 18. History of eye trauma or disease, retinopathy, and/or cataract of a level that would significantly affect transmission or processing of light through either eye 19. Ishihara score of \<10 on the Ishihara Test for Color Deficiency 20. Use of medications, such as tetracycline or oral isoretinoin (Accutane), that would affect the safety of light exposure treatment or that causes complaints of eyestrain or abnormal tearing with computer use of up to 30 minutes at a time

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
light therapy using 467nm LED source, within 30 minutes of waking in the morning every day for 6 weeks

Group II

Active Comparator
light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 4 locations

Suspended

McLean Hospital

Belmont, United StatesOpen McLean Hospital in Google Maps
Suspended

Brigham & Women's Hospital

Boston, United States
Suspended

University of Minnesota

Minneapolis, United States
Suspended

Community Research Management Associates

Cincinnati, United States
Completed4 Study Centers